semaglutide deaths 2024 Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly significantly reduced risks of major kidney events, cardiovascular events, and death from any cause Study Shows 58% Of Patients

Tips for Reducing the Risk of Rash Development To prevent rashes from occurring, it is important to follow some basic guidelines

There happen to be some very helpful and newer medications that have come out recently that show special promise in treating patients with PCOS

Comparing reconstitution approaches across GLP-1 peptides Semaglutide is not the only GLP-1 receptor agonist that researchers work with

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

It works by mimicking a natural hormone that signals the brain to eat less, making calorie control easier without constant hunger struggles

Eine retrospektive Kohortenstudie hat nun erstmals die Wirksamkeit und Sicherheit von GLP-1-Rezeptoragonisten bei nierentransplantierten Patient:innen mit Diabetes analysiert